VSDHOne

Search documents
Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
Globenewswire· 2025-09-02 12:24
Core Viewpoint - Hydreight Technologies Inc. has entered into a strategic partnership with Perfect Scripts LLC, which includes acquiring a 5% membership interest in Perfect Scripts and establishing a 503B pharmacy in the U.S. [1][2] Company Overview - Hydreight Technologies Inc. operates a fully integrated mobile clinical network in North America, comprising over 2,500 nurses and 100 doctors, along with a pharmacy network across all 50 states [13][14]. - Perfect Scripts LLC is the parent company of PerfectRx LLC and PerfectionRx LLC, which operate pharmacies and provide pharmaceutical services [6][9]. Transaction Details - Hydreight will acquire a 5% membership interest in Perfect Scripts for 2,250,000 common shares, with a deemed price of CAD$2.30 per share or the lowest price permitted by the TSX Venture Exchange [2]. - The partnership will allow Hydreight to receive the lowest pricing for products sold by Perfect Scripts and grants the right to maintain and increase its membership interest up to 40% [2][3]. Financial Aspects - A cash finder's fee of $258,750 will be paid to a finder in connection with the transaction, representing 5% of the deemed value [3]. - The Hydreight Compensation Shares will vest in increments and are subject to a four-month statutory hold period under Canadian securities laws [4][5]. Strategic Implications - The partnership is expected to enhance Hydreight's pharmacy margins, secure a consistent supply chain, and provide vertical integration, which will strengthen its market position [6][8]. - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight and Perfect Scripts [8]. Operational Capabilities - PerfectRx LLC operates a 30,000 sq ft licensed pharmacy and distribution center in Florida and can process over 150,000 prescriptions per day [7][10]. - The proprietary technology, PerfectOS, enables efficient digital prescription intake and real-time inventory management, enhancing operational efficiency [10][11]. Future Outlook - The partnership is viewed as a critical step in transforming access to modern healthcare and expanding Hydreight's product lineup [8]. - The VSDHOne platform, developed in partnership with Victory Square Technologies, aims to simplify the entry for companies into the online healthcare space, further supporting Hydreight's growth strategy [15].
Hydreight Posts Record VSDHOne Growth, Ahead of 2025 Targets
Globenewswire· 2025-08-12 12:00
June and July orders surge; Perfect Scripts + 503B partnership boosts scale VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) ("Hydreight" or the "Company"), a leader in nationwide digital healthcare solutions, is pleased to provide a corporate update highlighting record-breaking VSDHOne order growth, the strategic benefits of its newly announced Perfect Scripts partnership and 503B compounding capabilities. VSDHOne Order Growth Sur ...
Hydreight Technologies to Present at Maxim Group’s 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
Globenewswire· 2025-05-14 12:00
Core Insights - Hydreight Technologies Inc. is a rapidly growing digital health platform focused on transforming mobile and telehealth services in the U.S. [1] - The company will present at two investor conferences in June 2025, showcasing its healthcare infrastructure and technology platform [1][2] - Recent financial results indicate significant growth, with adjusted revenue increasing by 31% year-over-year [6] Financial Performance - FY2024 Adjusted Revenue reached $22.32 million CAD, a 31% increase year-over-year [6] - GAAP Revenue was reported at $16.04 million CAD, reflecting a 39% year-over-year growth [6] - Adjusted EBITDA improved to +$490,000 CAD, compared to a loss of -$1.38 million CAD in FY2023 [6] - Cash Flow from Operations was positive at +$857,000 CAD, with a current cash position of $6.8 million CAD [6] Business Expansion - In 2024, Hydreight expanded its service offerings to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications [4] - The company secured strategic partnerships with national health franchises and clinical experts, enhancing its service capabilities [4] - Hydreight has sold over 400 licenses to direct-to-consumer (D2C) brands across all 50 states, indicating strong market penetration [6] Technology and Platform Development - The VSDHOne platform was developed to facilitate compliant entry for companies into the online healthcare space, significantly reducing launch time and costs [9] - Hydreight's platform supports a network of over 3,000 nurses and 200 physicians, providing a comprehensive mobile clinic network across the U.S. [8] - The platform includes integrated tools for accounting, documentation, sales, inventory, and patient data management, enhancing operational efficiency for healthcare professionals [8]
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
Globenewswire· 2025-05-01 04:16
Core Insights - Hydreight Technologies Inc. has reported significant growth in its financial performance for the fiscal year 2024, achieving record revenues and positive Adjusted EBITDA, while focusing on scaling its VSDHOne platform for 2025 [2][6][9]. Financial Performance - The company achieved record topline revenue of CAD 22.32 million in 2024, representing a 31% increase from 2023 [6][17]. - GAAP revenue for 2024 was CAD 16.04 million, up 39% from CAD 11.51 million in 2023 [6][9]. - Adjusted EBITDA for 2024 was CAD 490,000, a turnaround from a loss of CAD 1.38 million in 2023 [6][17]. - The gross margin for 2024 was CAD 5.75 million, an increase of 8% from the previous year [6][17]. - The fourth quarter of 2024 saw revenues of CAD 4.04 million, a 20% increase compared to the same quarter in 2023 [7][9]. Strategic Focus for 2025 - The company plans to expand franchise white-label partnerships to enhance its market presence [13]. - There is a focus on increasing pharmacy margins through supply chain optimization and strategic pricing [14]. - New wellness categories will be launched, including NAD+, testosterone replacement therapy, and peptide therapies [14]. - The onboarding of high-growth D2C healthcare companies on the VSDHOne platform will be accelerated [15]. - The company aims to attract and support more licensed nurses to enhance its provider network [15]. - Strategic tuck-in acquisitions of complementary D2C health brands are being pursued to improve product mix and margins [15]. Recognition and Milestones - Hydreight was ranked 9 on Deloitte's 2024 Technology Fast 50 list and 56 on the Technology Fast 500 list for North America [6][9]. - The company completed its first post-IPO financing, raising CAD 5.4 million in February 2025 to support its growth initiatives [6][9]. Operational Highlights - The company operates a network of over 3,000 nurses and 200+ physicians across all 50 states, facilitating a scalable telehealth and at-home care model [11][12]. - Hydreight's VSDHOne platform supports over 400 Direct to Consumer license holders, enabling rapid entry into the online healthcare space [11][21].